Search Results - "Melendres‐Groves, Lana"

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic by Ryan, John J., Melendres-Groves, Lana, Zamanian, Roham T., Oudiz, Ronald J., Chakinala, Murali, Rosenzweig, Erika B., Gomberg-Maitland, Mardi

“…The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard…”
Get full text

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS) by McLaughlin, Vallerie V., Channick, Richard, Kim, Nick H., Frantz, Robert P., McConnell, John W., Melendres‐Groves, Lana, Miller, Chad, Ravichandran, Ashwin, Rodriguez‐Lopez, Josanna, Brand, Monika, Leroy, Sandrine, Wetherill, Graham, Chin, Kelly M.

“…Macitentan is an oral endothelin receptor antagonist for the management of pulmonary arterial hypertension (PAH). The OPsumit® USers Registry (OPUS) and the…”
Get full text

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil by Kingrey, John F, Miller, Chad E, Franco, Veronica, Smith, Jimmy S, Zolty, Ronald, Oudiz, Ronald J, Elwing, Jean M, Huston, Jessica H, Melendres-Groves, Lana, Ravichandran, Ashwin, Balasubramanian, Vijay, Wu, Benjamin, Hwang, Stephanie, Seaman, Scott, Broderick, Meredith, Rahaghi, Franck F

“…Treprostinil is a prostacyclin analogue that targets multiple cellular receptors to treat pulmonary arterial hypertension (PAH). In certain scenarios, patients…”
Get full text

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting by Balasubramanian, Vijay P., Safdar, Zeenat, Sketch, Margaret R., Broderick, Meredith, Nelsen, Andrew C., Lee, Dasom, Melendres‐Groves, Lana

“…Real‐world dosing and titration of parenteral (subcutaneous, SC; intravenous, IV) prostacyclin, a mainstay of pulmonary arterial hypertension (PAH) treatment,…”
Get full text

Real-world experience with riociguat as potential bridging therapy in patients with chronic thromboembolic pulmonary hypertension: a case series by Balasubramanian, Vijay P., Beutner, Matthew, Gill, Kirat, Kakol, Monika, Melendres-Groves, Lana

Get full text

Utilization of risk assessment tools in management of PAH: A PAH provider survey by Sahay, Sandeep, Balasubramanian, Vijay, Memon, Humna, Poms, Abby, Bossone, Eduardo, Highland, Kristine, Kay, Dana, Levine, Deborah J, Mullin, Christopher J, Melendres‐Groves, Lana, Mathai, Stephen C, Soto, Francisco J, Shlobin, Oksana, Elwing, Jean M

“…Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal‐oriented approach to achieve low risk status has been associated with…”
Get full text

Pulmonary Hypertension Care Center Network by Sahay, Sandeep, MD, Melendres-Groves, Lana, MD, Pawar, Leena, MBBS, Cajigas, Hector R., MD

“…Pulmonary hypertension (PH) is a chronic, progressive, life-threatening disease that requires expert multidisciplinary care. To facilitate this level of care,…”
Get full text

Evolving nonvasodilator treatment options for pulmonary arterial hypertension by Medrek, Sarah, Melendres-Groves, Lana

“…Purpose of review With the establishment of vasodilator therapy as a mainstay of treatment for pulmonary arterial hypertension (PAH), new therapeutic…”
Get full text

Evolving nonvasodilator treatment options for pulmonary arterial hypertension by Medrek, Sarah, Melendres-Groves, Lana

Get full text

Imaging in Pulmonary Vascular Disease-Understanding Right Ventricle-Pulmonary Artery Coupling by Tsarova, Katsiaryna, Morgan, Ashley E, Melendres-Groves, Lana, Ibrahim, Majd M, Ma, Christy L, Pan, Irene Z, Hatton, Nathan D, Beck, Emily M, Ferrel, Meganne N, Selzman, Craig H, Ingram, Dominique, Alamri, Ayedh K, Ratcliffe, Mark B, Wilson, Brent D, Ryan, John J

“…The right ventricle (RV) and pulmonary arterial (PA) tree are inextricably linked, continually transferring energy back and forth in a process known as RV-PA…”
Get more information

CURRENT TREATMENT PATTERNS IN PULMONARY ARTERIAL HYPERTENSION (PAH): REAL-WORLD DATA FROM A CONTEMPORARY U.S. PHYSICIAN SURVEY by MELENDRES-GROVES, LANA, NELSON, GINA, NGUYEN, SANDY, NUNEZ PEREZ, RAQUEL, BROWN, SARAH, PRESTON, IOANA R

Get full text

Untangling BNP and BMI by Medrek, Sarah K., Melendres-Groves, Lana

Get full text

Abstract 12978: Real-World Treatment Patterns in Hispanic and White Patients With Pulmonary Arterial Hypertension (PAH) in the United States by Melendres-Groves, Lana, Tang, Wenze, Germack, Hayley D, Liu, Zhiwen, Sadik, Kay

“…Abstract only Introduction: ESC/ERS guidelines recommend initial double oral combination therapy (endothelin-receptor antagonist plus phosphodiesterase 5…”
Get full text

Racial disparities in treatment patterns, healthcare resource use, and outcomes in patients with pulmonary arterial hypertension in the United States by Melendres-Groves, Lana, Tang, Wenze, Germack, Hayley D, Liu, Zhiwen, Sadik, Kay

“…This retrospective study using claims data compared demographics, clinical characteristics, treatment patterns, healthcare resource utilization, and clinical…”
Get full text

CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION BY RACE: REAL-WORLD DATA FROM THE COMBINED OPUS/ORPHEUS STUDIES by MCLAUGHLIN, VALLERIE, CHANNICK, RICHARD N, MELENDRES-GROVES, LANA, CHIN, KELLY, MACDONALD, GWEN, MARTIN, NICOLAS, ONG, ROSE, SANDROS, MARINELLA, KIM, NICK H

Get full text

CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES OF PULMONARY ARTERIAL HYPERTENSION PATIENTS BY ETHNICITY: REAL-WORLD DATA FROM THE COMBINED OPUS/ORPHEUS STUDIES by MELENDRES-GROVES, LANA, CHIN, KELLY, KIM, NICK H, MCLAUGHLIN, VALLERIE, MACDONALD, GWEN, MARTIN, NICOLAS, ONG, ROSE, SANDROS, MARINELLA, CHANNICK, RICHARD N

Get full text

Untangling BNP and BMI: Does Obesity Limit the Predictive Capability of BNP in PAH? by Medrek, Sarah K, Melendres-Groves, Lana

Get full text

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study by Nathan, Steven D, Waxman, Aaron, Rajagopal, Sudarshan, Case, Amy, Johri, Shilpa, DuBrock, Hilary, De La Zerda, David J, Sahay, Sandeep, King, Christopher, Melendres-Groves, Lana, Smith, Peter, Shen, Eric, Edwards, Lisa D, Nelsen, Andrew, Tapson, Victor F

“…INCREASE was a randomised, placebo-controlled, phase 3 trial that evaluated inhaled treprostinil in patients with interstitial lung disease (ILD) and…”
Get full text

Pulmonary Hypertension Care Center Network: Improving Care and Outcomes in Pulmonary Hypertension by Sahay, Sandeep, Melendres-Groves, Lana, Pawar, Leena, Cajigas, Hector R

“…Pulmonary hypertension (PH) is a chronic, progressive, life-threatening disease that requires expert multidisciplinary care. To facilitate this level of care,…”
Get full text

LONG-TERM SAFETY AND TOLERABILITY OF INHALED TREPROSTINIL IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE by WAXMAN, AARON B, M. ELWING, JEAN, MELENDRES-GROVES, LANA, G RISBANO, MICHAEL, J LENNEMAN, ANDREW, F TAPSON, VICTOR, SHEN, ERIC, SMITH, PETER, DENG, C.Q., D NATHAN, STEVEN

Get full text